Clinical Trials Logo

Polycythemia Vera clinical trials

View clinical trials related to Polycythemia Vera.

Filter by:

NCT ID: NCT01199562 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

Start date: December 2010
Phase:
Study type: Observational

RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant. PURPOSE:This clinical trial studies infection prophylaxis and management in treating cytomegalovirus infection in patients with hematologic malignancies previously treated with donor stem cell transplant.

NCT ID: NCT01193699 Completed - Polycythemia Vera Clinical Trials

Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera

PEGINVERA
Start date: August 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is the identification of the maximum tolerated dose (MTD) of the investigational medicinal product. Moreover the safety and tolerability will be assessed and an exploratory analysis of efficacy and biomarker modulation will be performed.

NCT ID: NCT01134120 Completed - Clinical trials for Primary Myelofibrosis

A Study in Myeloproliferative Disorders

Start date: April 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out the safe dose range of the study drug in patients with myeloproliferative disorders.

NCT ID: NCT01120821 Completed - Polycythemia Vera Clinical Trials

Treatment of Polycythemia Vera With Gleevec

Start date: August 2002
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to evaluate the safety and effectiveness of patients with Polycythemia Vera treated with Gleevec.

NCT ID: NCT01053494 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer

Start date: April 2010
Phase: N/A
Study type: Interventional

This clinical trial studies massage therapy given by caregiver in treating quality of life of young patients undergoing treatment for cancer. Massage therapy given by a caregiver may improve the quality of life of young patients undergoing treatment for cancer

NCT ID: NCT00952289 Completed - Clinical trials for MPN (Myeloproliferative Neoplasms)

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

Start date: August 2009
Phase: Phase 3
Study type: Interventional

This was a randomized, double-blind study comparing the efficacy and safety of ruxolitinib (INCB018424) tablets to matching placebo tablets in patients diagnosed with Myelofibrosis (either Primary Myelofibrosis (PMF) or Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

NCT ID: NCT00946270 Completed - Polycythemia Vera Clinical Trials

Pomalidomide for Myelofibrosis Patients

Start date: July 22, 2009
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if CC-4047 (now called pomalidomide) and prednisone can help to control MMM. The safety of this therapy will also be studied.

NCT ID: NCT00935987 Completed - Clinical trials for Primary Myelofibrosis

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Start date: November 2009
Phase: Phase 1/Phase 2
Study type: Interventional

This study seeks to (i) determine a safe and tolerated dose of CYT387 (momelotinib) given to patients with PMF, post-PV or post-ET and, (ii) assess the effectiveness of orally-administered CYT387 as a treatment for PMF, post-PV or post-ET.

NCT ID: NCT00934544 Completed - Myelofibrosis Clinical Trials

Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

Start date: July 1, 2009
Phase: Phase 3
Study type: Interventional

This was an open label, randomized study comparing the efficacy and safety of randomized 2:1 Ruxolitinib tablets versus best-available therapy, as selected by the investigator. The purpose was to compare the efficacy, safety and tolerability of Ruxolitinib (INC424/INCB018424) given twice daily to the best-available therapy, in subjects with primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (PPV-MF) or post essential thrombocythemia myelofibrosis (PET-MF).

NCT ID: NCT00928707 Completed - Polycythemia Vera Clinical Trials

Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera

PV
Start date: June 2009
Phase: Phase 2
Study type: Interventional

The primary objective of the study was to evaluate the efficacy of Givinostat in combination with hydroxyurea in patients with JAK2V617F-positive Polycythemia Vera (PV) non-responders to the maximum tolerated dose of hydroxyurea monotherapy. The secondary objectives of this study were: - To evaluate the safety and tolerability of Givinostat in combination with hydroxyurea in patients with JAK2V617Fpositive PV non-responders to the maximum tolerated dose of hydroxyurea monotherapy; - To explore the impact in terms of efficacy and tolerability of Givinostat 50 mg dose escalation in patients not achieving at least a partial response at the time when the primary endpoint was assessed (week 12); - To evaluate the molecular response (JAK2 mutated allele burden) by quantitative Real Time-Polymerase Chain Reaction (RT-PCR); - To evaluate the reduction of the fraction of JAK2V617F positive clonogenic progenitors.